Atom Therapeutics

Privately held: no public share price

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 2
NLRP3 inflammasomeSmall molecule
Atherosclerotic Cardiovascular Disease
Phase 2
URAT1 (urate transporter 1, SLC22A12)Small molecule
Chronic Kidney Disease

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
October 2027 (1)
LingdolinuradPhase 2Chronic Kidney Disease
Est. primary completion 2027-10-31 · NCT07323095 · CT.gov ↗
What to watch
2028 (1)
January 2028 (1)
ABP-745Phase 2Atherosclerosis Cardiovascular Disease, ASCVD, ASCVD Management
Est. primary completion 2028-01 · NCT07303777 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 September 2025Topline resultLingdolinurad (ABP-671)Positive topline results from the global Phase 2b/3 trial of lingdolinurad (ABP-671) in chronic gout
Atom Therapeutics · Source ↗

Financial reports

No financial reports recorded.